What is the purpose of this trial?
The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.
Blood and Marrow Transplant Clinical Trials Network
Start Date: 03/22/2019
End Date: 08/01/2024
Last Updated: 03/25/2019
Study HIC#: 2000022156